Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MaxCellLife MIND
- Development stage
- Unknown
- Lead developer
- Key Capital Corporation
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**MaxCellLife MIND** is an oral multi-ingredient dietary supplement developed by Key Capital Corporation in partnership with Immunitor, positioned as a gut-brain support product for people dealing with anxiety, stress, and depression. The formulation is described as containing a proprietary blend of **Mycobacterium vaccae**, ionic magnesium chloride hexahydrate, calcium, and collagen, delivered as an oral pill using Immunitor's patented oral delivery technology intended to protect active ingredients through the gastrointestinal tract. Its proposed mechanism is nutraceutical and microbiome-oriented rather than a validated pharmaceutical mechanism, with the psychobiotic component **M. vaccae** promoted as supporting the gut-brain axis and potentially influencing serotonin-associated mood pathways; however, specific target-level pharmacology and clinical efficacy for the finished branded product are not established in the provided materials.
- Brand names
- MaxCellLife MIND
Beyond the preview
Go deeper on MaxCellLife MIND.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MaxCellLife MIND.